TIDMGENI
RNS Number : 6856T
GENinCode PLC
26 July 2022
GENinCode Plc
("GENinCode" or the "Company")
NHS implementation of Lipid inCode (R) testing of patients
suffering with hypercholesterolemia and familial
hypercholesterolemia
Lipid inCode(R) becomes the first commercial polygenic test for
CVD to be implemented by the NHS
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics
company focused on the prevention of cardiovascular disease,
announces the expansion of its collaboration with the Academic
Health Science Network for the North East and North Cumbria ("AHSN
NENC") to implement the use of its Lipid inCode(R) test in the AHSN
NENC Primary Care Network (PCN) for the diagnosis of
hypercholesterolemia (high levels of cholesterol) and familial
hypercholesterolemia ("FH"). This marks the introduction of
GENinCode's first UK polygenic product aimed at improving the
diagnosis and treatment of hypercholesterolemia and preventing the
onset of cardiovascular disease ("CVD").
There are 15 Academic Health Science Networks ("AHSN") across
England, established by NHS England in 2013 to spread innovation at
pace and scale - improving health and generating economic growth.
Each AHSN works across a distinct geography serving a different
population in each region. The AHSN NENC leads a national AHSN
programme aimed at identification of FH and lipid management, in
collaboration with the Accelerated Access Collaborative (AAC) and
the National Institute for Health & Care Excellence (NICE).
The NHS implementation of Lipid inCode(R) marks the introduction
of GENinCode's first UK genetic product aimed at improving the
diagnosis and treatment of familial hypercholesterolemia and
preventing the onset of cardiovascular disease ("CVD"). Lipid
inCode(R) is the first commercial polygenic test for CVD to be
implemented by the NHS.
Following the positive results of its Lipid inCode(R) NHS
clinical study (1) and recent successful completion of the Lipid
inCode(R) AHSN NENC pilot, the AHSN NENC will now implement the use
of Lipid inCode(R) in the Darlington PCN and community practice
representing over 100,000 patients in the North of England. Within
this population, Lipid inCode will detect and diagnose people with
high cholesterol, a known important risk factor for the development
of CVD. Improved detection supports better treatment and
preventative care. Lipid inCode(R) offers genetic testing for the
causes of high cholesterol, with rapid results and comprehensive
reporting for clinicians. Lipid inCode(R) will be offered at a
reduced cost to the NHS, to help support the ambition it declared
in its Long Term Plan to detect 25% of people with FH by 2024.
In the UK around 7.6m people live with heart and circulatory
disease, which causes 25% of all deaths annually in the UK. CVD can
be reduced by identifying and treating individuals at risk, and the
NHS 10 Year Plan (2019) sets out significant ambitions to address
the CVD prevention, including identifying individuals with
hypercholesterolemia and particularly those with FH.
FH is an inherited monogenic condition which affects an
individual's ability to regulate and remove cholesterol from their
blood. FH affects approximately one in 250 people in the UK
population and globally. The NHS Long Term Plan sets out to expand
access to genetic testing for FH, which causes early heart attacks
and sudden cardiac death. Individuals suffering with FH have a
higher risk of heart disease and death at a younger age. For
individuals suffering with FH it is important to lower their
cholesterol to healthy levels as early in life as possible, often
requiring medicines such as statins or more aggressive treatment to
help better control cholesterol levels.
CVD is a broad disease classification which encompasses
conditions such as coronary artery disease (causing angina, heart
attacks, heart failure), cerebrovascular disease (causing stroke,
and some dementia), peripheral vascular disease (causing limb
ischemia, and some chronic kidney disease) and venous
thromboembolism. CVD is the leading cause of death and disability
worldwide accounting for one in every four deaths in the United
States. According to the US National Institutes of Health (NIH), by
2030, the global cost of CVD is set to rise to US$1,044 billion,
from approximately US$863 billion in 2010, and is both a major
health issue and global economic burden.
GENinCode has a vision to assist clinicians and inform patients
in interpreting cardiovascular risk, and to improve public health
using the predictive capability of genomics. High genetic risk
patients are assisted in making lifestyle choices and can receive
targeted treatment to improve outcomes. Over the past 15 years
GENinCode has made a substantial investment in its research,
bioinformatic data, technology, and product development to assess
disease risk, in order to help clinicians and patients prevent the
onset of CVD.
Matthew Walls, CEO of GENinCode PLC said: "The collaboration
with the AHSN NENC continues to advance our Lipid inCode test to
identify patients at high risk of heart disease and stroke
representing the largest cause of death in the UK. The
implementation of Lipid inCode marks the beginning of our NHS
diagnostic testing for hypercholesterolemia and familial
hypercholesterolemia sufferers and we look forward to supporting
the NHS in reaching its long term plan to diagnose patients with
hypercholesterolemia."
Professor Julia Newton, Medical Director at AHSN NENC commented:
"We are delighted to now move into the implementation phase for
Lipid inCode(R) to advance the diagnosis and treatment of
hypercholesterolemia and familial hypercholesterolemia. With the
added benefit of easy sample collection, improved test turnaround
times at a reduced costs to the NHS, we can start to deliver the
Lipid inCode test in our primary care practice and welcome this
approach to help support and deliver the NHS 10-Year plan to reduce
the onset of cardiovascular disease."
For more information visit www.genincode.com
Enquiries:
GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO
Paul Foulger, CFO
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
Walbrook PR Limited Tel: 020 7933 8780 or genincode@walbrookpr.com
Anna Dunphy / Paul McManus / Louis Ashe-Jepson
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk
assessment of cardiovascular disease. Cardiovascular disease is the
leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through
GENinCode S.L.U, and in the United States through GENinCode U.S.
Inc.
GENinCode predictive technology provides patients and physicians
with globally leading preventative care and treatment strategies.
GENinCode CE marked invitro-diagnostic molecular tests combine
clinical algorithms and bioinformatics to provide advanced patient
risk assessment to predict disease onset.
About Academic Health Science Network for the North East and
North Cumbria (AHSN NENC):
The AHSN NENC is focused on building and maintaining strong
relationships and partnerships which is fundamental to its success.
Member organisations and stakeholders include NHS, academia and
industry partners in the North East and North Cumbria.
By developing and maintaining strong relationships with members
and practitioners, the Network continually shares knowledge and
translates ideas into practice. The Network benefits from
harnessing the expertise and experience of clinical staff, for
example, to act as change agents to adopt and diffuse new practice
across organisations and support the research community to develop
knowledge.
To deliver against what is a broad remit, the Network works in
close collaboration with The AHSN Network across the UK as well as
with other national organisations, such as NIHR Clinical Research
Network . Other partnerships are developed where appropriate, for
example, with the third sector and with industry.
About Cardiovascular Disease (CVD):
Heart and circulatory disease, also known as cardiovascular
disease, causes a quarter of all deaths in the UK and is the
largest cause of premature mortality in deprived areas and is the
single biggest area where the NHS can save lives over the next 10
years. CVD is largely preventable, through lifestyle changes and a
combination of public health and NHS action on smoking and tobacco
addiction, obesity, tackling alcohol misuse and food
reformulation.
Early detection and treatment of CVD can help patients live
longer, healthier lives. Many people are still living with
undetected, high-risk conditions such as high blood pressure,
raised cholesterol, and atrial fibrillation (AF). Progress
continues in the NHS to identify and diagnose people routinely
knowing their 'ABC' (AF, Blood pressure and Cholesterol).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBELLLLDLLBBE
(END) Dow Jones Newswires
July 26, 2022 02:00 ET (06:00 GMT)
Genincode (LSE:GENI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genincode (LSE:GENI)
Historical Stock Chart
From Apr 2023 to Apr 2024
